



CIN : L99999MH1951PLC008485

Regd. Office : A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India  
Tel : +91-22-67980888 , ● Fax : +91-22-67980899 , ● Email : [contact@dil.net](mailto:contact@dil.net) , ● Website: [www.dil.net](http://www.dil.net)

Ref: DIL:DIL/BSE/2019-20/F.No.:49

August 5, 2019

**Corporate Relations  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001**

Dear Sir,

**Sub.: Intimation of Earnings Release dated August 5, 2019**

**Ref: Scrip Code: 506414**

Further to our intimation dated August 5, 2019 regarding approval of Unaudited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter ended June 30, 2019, we hereby enclose a copy of Earnings Release of the Company for the quarter ended June 30, 2019.

The said Earnings Release is also available on Company's website [www.dil.net](http://www.dil.net)

Kindly take the same on records.

Thanking you,

Yours faithfully,  
for **DIL LIMITED**

**Srikant N Sharma  
Company Secretary**

CS Membership No: F3617

*A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610*

Encl: As above

## DIL Limited

### Sustainable performance continues in Q1 FY20

#### Consolidated Financial Performance – Q1 FY20

- Total Revenue (including other income) at Rs. 84.09 Cr as against Rs 83.45 Cr in Q1 FY19
- EBITDA (including other income) at Rs. 27.42 Cr, margin is at 32.6%
- PAT at Rs. 14.06 Cr as against Rs 16.68 Cr in Q1 FY19

**Mumbai, 5<sup>th</sup> August 2019:** DIL Limited announced its unaudited financial results for the quarter ended 30th June, 2019.

DIL Limited (Consolidated Results)			
Particulars (Rs. Crs)	Q1 FY20	Q1 FY19	YoY%
Revenue*	84.1	83.5	0.8%
EBITDA*	27.4	29.2	-6.2%
Margin (%)	33%	35%	
PAT	14.1	16.7	-15.7%
Margin (%)	17%	21%	

\*includes other income

#### Un-audited Results of Fermenta Biotech Limited, 91.2% Subsidiary of DIL Limited

Fermenta Biotech Limited (FBL) is the only manufacturer and supplier of Vitamin D3 (Cholecalciferol) in India and amongst the leading players globally. Apart from Vitamin D3, Fermenta also possesses expertise in integrated biotechnology solutions such as enzymes for antibiotic synthesis and other niche APIs.

Fermenta Biotech Limited			
Particulars (Rs. Crs)	Q1 FY20	Q1 FY19	YoY%
Revenue*	80.1	79.7	0.5%
EBITDA*	26.9	28.7	-6.1%
Margin (%)	34%	36%	
PAT	16.3	21.1	-22.9%
Margin (%)	20%	26%	

\*includes other income

## Earnings Release

### **Business Updates:**

During the quarter, Fermenta Biotech Limited had taken a planned shutdown of Dahej plant to carry out major repairs and maintenance work and de-bottlenecking programme which was completed on May 29, 2019. Post completion of this de-bottlenecking programme, the production capacity has increased by approximately 15%. The de-bottlenecking programme is part of the overall strategy of FBL to increase the production capacity.

### **Merger Update:**

The shareholders and creditors of DIL Limited and Fermenta Biotech Limited have approved the merger of Fermenta Biotech Limited into DIL Limited by voting on 8<sup>th</sup> July 2019 at the NCLT convened meeting. The merger process is awaiting final approval of NCLT. Post the merger, the name of DIL Limited will be changed to Fermenta Biotech Limited.

**Commenting on the performance, Mr. Satish Varma, Managing Director, Fermenta Biotech Ltd. said,** “The start of the new financial year has been satisfactory with Q1 FY20 Revenue at Rs. 84.1 crs as against Rs 83.5 crs for Q1 FY 19 despite nearly one-month maintenance and de-bottlenecking shutdown taken in May 2019.

During the quarter, the Revenue from Vitamin D3 for Pharmaceutical use has been Rs. 34 cr and contributed 45% to overall revenue as compared to 29% in Q1FY19. The Revenue from Vitamin D3 for Animal Feed use has been Rs. 31 cr and contributed 41% to overall revenue as compared to 47% in Q1FY19. The prices of Vitamin D3 for Animal Feed have shown weaker tone as compared to earlier quarters.

Recently one of our largest Vitamin D3 customer has indicated that due to technical issues at their production facility, they would not be able to manufacture their product till the end of this year, therefore we anticipate a decrease in Vitamin D3 Animal Feed demand for the coming few quarters from this customer.

Regarding our capex plan at Sayakha in Gujarat, we are ready with our internal planning and are waiting for the Environmental Clearance approval. Once received, we will be able to move forward with the plans quickly. The capex will help us to increase our manufacturing capacity of Vitamin D3 and forward integrate into Dietary Nutritional Supplement products.

Looking at the demand for Vitamin D3 backed by growing awareness, we continue to believe that the volume will continue to grow at 15-20% CAGR over the next 5 years.”

## Earnings Release

### **About DIL Limited:**

DIL holds 91.2% equity stake in Fermenta Biotech Limited (FBL), which was incorporated in 1986.

FBL is engaged in manufacturing of Vitamin D3, other specialty APIs, biological enzymes and also offers integrated biotech based environmental solutions. FBL has 2 manufacturing facilities:

- Kullu in Himachal Pradesh – cGMP certified and currently manufactures Vitamin D3, specialty API’s and Enzymes
- Dahej SEZ – set up in 2011 and manufactures Vitamin D3

DIL has developed premium office spaces named ‘THANE ONE’, with a total leasable area of 200,000 sq. ft., which is 100% occupied.

For more information about the Company and its businesses, please visit our website [www.dil.net](http://www.dil.net)

### **Safe Harbor:**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

### **For further details please contact:**

Company	Investor Relations Advisors
<p><b>DIL Limited</b>            CIN No: L99999MH1951PLC008485            Name: Sumesh Gandhi            Email id: <a href="mailto:sumesh.gandhi@dil.net">sumesh.gandhi@dil.net</a></p>	<p><b>Strategic Growth Advisors Pvt Ltd.</b>            CIN No: U74140MH2010PTC204285            Name: Jigar Kavaia            Email id: <a href="mailto:jigar.kavaia@sgapl.net">jigar.kavaia@sgapl.net</a>            Tel No: +91 9920602034</p>